F-group (family)
309.1.1.2 Peptidase_M16,Peptidase_M16_C
Ligands and drugs
829
Member domains
187
with ligand contacts (≤ 4 Å)
22.6% of members
243
with DrugDomain annotations
29.3% of members
78
with a DrugBank compound
9.4% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 309.1.1.2 belongs to X-group 309 LuxS, MPP, ThrRS/AlaRS common domain, which binds 6.7 ligand superclasses per 20 proteins, narrower than 64% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB09114 | PCF | Colfosceril palmitate | 14 |
| DB04327 | PEE | Phosphatidylethanolamine | 9 |
| DB02686 | UMQ | Undecyl-Beta-D-Maltopyranoside | 7 |
| DB03429 | CDL | Tetrastearoyl cardiolipin | 3 |
| DB01677 | FUM | Fumaric acid | 2 |
| DB03988 | LYN | 2,6-Diamino-Hexanoic Acid Amide | 2 |
| DB00608 | CLQ | Chloroquine | 1 |
| DB00626 | — | — | 1 |
| DB01728 | PEF | 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine | 1 |
| DB04141 | — | 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol | 1 |
| DB04741 | — | Myxothiazol | 1 |
| DB04799 | — | 6-Hydroxy-5-undecyl-4,7-benzothiazoledione | 1 |
| DB07401 | — | Azoxystrobin | 1 |
| DB07763 | — | (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE | 1 |
| DB07778 | — | (S)-famoxadone | 1 |
| DB08330 | — | METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE | 1 |
| DB08453 | — | 2-Nonyl-4-quinolinol 1-oxide | 1 |
| DB08690 | — | Ubiquinone Q2 | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ZNmetal | ZINC ION | 147 |
| CL | CHLORIDE ION | 6 |
| UNL | Unknown ligand | 5 |
| J22 | {(8R,9S,10S)-9-(2',3'-dimethyl[1,1'-biphenyl]-4-yl)-6-[(1-methyl-1H-imidazol-2-yl)sulfonyl]-1,6-diazabicyclo[6.2.0]decan-10-yl}methanol | 4 |
| AZI | AZIDE ION | 3 |
| COmetal | COBALT (II) ION | 3 |
| 2H7 | 4-fluoro-N-({1-[(2R)-4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)benzamide | 2 |
| 2PJ | tert-butyl [(2S)-2-(2,5-difluorophenyl)-3-(quinolin-3-yl)propyl]carbamate | 2 |
| 2Q6 | methyl [(2S)-2-[4-({5-[4-({(2S)-2-[(3S)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl}amino)phenyl]pentyl}oxy)phenyl]-3-(quinolin-3-yl)propyl]carbamate | 2 |
| 2QX | methyl [(2S)-2-(5-{5-[4-({(2S)-2-[(3S)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl}amino)phenyl]pentyl}-2-fluorophenyl)-3-(quinolin-3-yl)propyl]carbamate | 2 |
| 3M9 | 4-fluoro-N-({1-[(2R)-4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl]-1H-1,2,3-triazol-5-yl}methyl)benzamide | 2 |
| 3UE | [4-(diphenylmethyl)piperazin-1-yl](3-methyl-4-nitrophenyl)methanone | 2 |
| I41 | 2-[[2-[[(2S)-3-(3H-IMIDAZOL-4-YL)-1-METHOXY-1-OXO-PROPAN-2-YL]AMINO]-2-OXO-ETHYL]-(PHENYLMETHYL)AMINO]ETHANOIC ACID | 2 |
| J18 | [(8R,9S,10S)-9-(2',3'-dimethyl[1,1'-biphenyl]-4-yl)-6-{[2-(trifluoromethyl)phenyl]sulfonyl}-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol | 2 |
| QIX | N~2~-[(2R)-4-(HYDROXYAMINO)-2-(2-NAPHTHYLMETHYL)-4-OXOBUTANOYL]-L-ARGINYLGLYCYLGLYCINAMIDE | 2 |
| VQD | (3R)-3-{4-[(3R)-4-(3,4-difluorobenzene-1-carbonyl)morpholin-3-yl]-1H-1,2,3-triazol-1-yl}-N-hydroxy-4-(naphthalen-2-yl)butanamide | 2 |
| VQG | 3,4-difluoro-N-[(1S)-1-{1-[(2R)-4-(hydroxyamino)-4-oxo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)butan-2-yl]-1H-1,2,3-triazol-4-yl}ethyl]benzamide | 2 |
| VQJ | 3,4-difluoro-N-({1-[(2R)-4-(hydroxyamino)-4-oxo-1-(quinolin-7-yl)butan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)benzamide | 2 |
| 1EF | N-({1-[(2R)-4-(hydroxyamino)-1-(naphthalen-2-yl)-4-oxobutan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)-4-methylbenzamide | 1 |
| H8F | 2-(aminomethyl)-3,5-ditert-butyl-phenol | 1 |